MYCN and neuroblastoma: As with epigenetic drugs used in cancer cells, neuroblastoma cells lacking MYCN also have an enriched H3K4me2 permissive mark combined with a reduction in the repressive marks H3K27me3 and H3K9me3 in the CLU promoter region [80].